Triple-Negative Receptor Conversion at Metastatic Sites Might Show Better Efficacy in Patients Who Received Sacituzumab Govitecan.

MLA

Altundag, Kadri. “Triple-Negative Receptor Conversion at Metastatic Sites Might Show Better Efficacy in Patients Who Received Sacituzumab Govitecan.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 41, no. 8, Mar. 2023, p. 1630. EBSCOhost, https://doi.org/10.1200/JCO.22.01961.

APA

Altundag, K. (2023). Triple-Negative Receptor Conversion at Metastatic Sites Might Show Better Efficacy in Patients Who Received Sacituzumab Govitecan. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 41(8), 1630. https://doi.org/10.1200/JCO.22.01961

Chicago

Altundag, Kadri. 2023. “Triple-Negative Receptor Conversion at Metastatic Sites Might Show Better Efficacy in Patients Who Received Sacituzumab Govitecan.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 41 (8): 1630. doi:10.1200/JCO.22.01961.